ELCC 2019 | NSCLC: a treatment landscape in flux in the checkpoint inhibitor era

Martin Reck

The treatment landscape of non-small cell lung cancer (NSCLC) is in a state of flux, with novel immuno-oncology agents and combinations at the forefront. Here, Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, gives his insight into this changing field and the future considerations. This interview took place at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.

Share this video